Rare diseases
Investigational molecules
Locations
Study of telisotuzumab adizutecan plus drug combination in adults with refractory metastatic colorectal cancer
BelgiumTelisotuzumab Adizutecan for Locally Advanced or Metastatic Solid Tumors with MET Amplification in Patients 12 Years and Older
DenmarkA Study of Telisotuzumab Adizutecan Compared to Standard Treatment in Adults with Advanced Non-Small Cell Lung Cancer After Previous Treatment
AustriaStudy of telisotuzumab adizutecan with osimertinib as first treatment for adults with advanced or metastatic EGFR-mutated non-small cell lung cancer
BelgiumStudy of Telisotuzumab Adizutecan for Adults with Colorectal Cancer Who Have Positive Circulating Tumor DNA After Treatment but No Visible Cancer on Scans
BelgiumStudy on the Safety and Effectiveness of Telisotuzumab Adizutecan and Drug Combination for Patients with Metastatic Colorectal Cancer
AustriaStudy of ABBV-400 and Budigalimab for Adults with Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
BelgiumPhase 2/3 study of telisotuzumab adizutecan with drug combination versus standard care in adults with first‑line metastatic pancreatic ductal adenocarcinoma
AustriaA Study Comparing Telisotuzumab Adizutecan to Trifluridine, Tipiracil, and Bevacizumab in Adults with Refractory Metastatic Colorectal Cancer
FranceStudy on ABBV-400, Fluorouracil, Leucovorin, and Budigalimab for Advanced or Metastatic Stomach and Esophageal Cancer Patients
BelgiumStudy on ABBV-400 with Fluorouracil, Folinic Acid, and Bevacizumab for Adults with Unresectable Metastatic Colorectal Cancer
BelgiumTell us about your condition – we search every trial in Europe and connect you with the right site.
